Financing risk
The company does not yet generate operating cash flow and depends on external capital.
- Scope
- Ongoing R&D and study funding
- Materiality
- high
Scandinavian Real Heart
Scandinavian Real Heart AB is a Swedish medical technology company developing the Realheart® TAH, a total artificial heart intended to replace the native heart in patients with severe heart failure. The company is based in Västerås, Sweden, and its work spans device development, preclinical testing, intellectual property protection, and regulatory preparation.
| % | |
|---|---|
| Total artificial heart systems | 70% Implantable cardiac replacement systems designed to support or replace the failing heart. |
| External control units | 15% Wearable control hardware used to operate and monitor the heart system. |
| Preclinical development services | 10% Testing, validation, and study work supporting device advancement toward clinical use. |
| Intellectual property and licensing-related assets | 5% Patents and related technology rights that protect the platform and future commercialization. |
The company’s direct customers are not commercial buyers today; its near-term counterparties are hospitals, clinical...
- Hospital research partnersprimary
They collaborate on acute and chronic implantation studies to generate safety and performance evidence.
- Regulators and notified bodiesprimary
They review the device, testing data, and clinical pathway before human use.
- Future cardiac centerssecondary
They would evaluate and purchase the system for advanced heart failure treatment once approved.
- Patients with severe heart failuresecondary
They are the eventual beneficiaries of the device, though not direct purchasers.
The company is headquartered in Västerås, Sweden, and its current development work is centered in Sweden, including...
- •Headquartered in Västerås, Sweden
- •Preclinical collaboration with Sahlgrenska University Hospital near Gothenburg
- •Regulatory pathway includes the EU and the United States
- •Patent coverage extends across Europe, the US, China, Japan, and India
The company’s near-term strategy is to complete preclinical work on the controller and heart pump, then use the...
01
Complete preclinical validationshort-term
The device must demonstrate safety, handling, and physiologic stability before clinical studies can begin.
02
Advance regulatory readinessmedium-term
Parallel engagement with EU and US regulators shortens the path to first-in-human use.
03
Strengthen intellectual propertymedium-term
Patent protection supports future commercialization and reduces competitive imitation risk.
04
Maintain funding capacityshort-term
Long development cycles require ongoing capital to fund testing and regulatory work.
The business depends on successful completion of demanding preclinical and regulatory milestones, and delays in testing...
Preclinical development risk
The company must complete hemolysis, endurance, and implantation studies before human trials.
- Scope
- Realheart® TAH and controller development
- Materiality
- high
Regulatory approval risk
EU and US pathways can require additional evidence, redesign, or longer review cycles.
- Scope
- Notified Body and FDA interactions
- Materiality
- high
Technical performance risk
The device must prove surgical usability, physiologic stability, and durability in testing.
- Scope
- Heart pump and external control unit
- Materiality
- high
IP and competitive risk
Protection must be broad enough to defend future commercialization in multiple markets.
- Scope
- Patent portfolio across major jurisdictions
- Materiality
- medium
Government and other grants
Affects operating income, intangible asset carrying values, and cash flow presentation
Capitalized development costs
Can materially affect balance sheet and future expense recognition
Impairment of intangible assets
Could reduce reported assets and earnings
Foreign currency translation
Can create translation differences in equity and reported results
Cash flow presentation of grants
Changes cash flow line items without changing total cash flow
: 11/08/2026